Abstract
BackgroundOvarian cancer (OC) is the second most common gynaecological malignancy. MicroRNAs (miRNAs) have been found to be aberrantly expressed in OC tissue and have been proposed as biomarkers and therapeutic targets for OC.ResultsIn this study, we found that miR-96-5p was up-regulated in OC tissues and OC cells compared to normal ovarian tissues and epithelial cell line. And, miR-96-5p was also up-regulated in the serum samples from OC patients compared to health participants. In addition, there was a positive correlation of miR-96-5p levels between OC tissues and serum samples. At the cellular level, overexpression of miR-96-5p promoted cell proliferation and migration in OC cells. Moreover, we further validated Caveolae1 (CAV1) as the direct target of miR-96-5p in OC cells through luciferase activity assays and western blot. CAV1 was obvious low expression in OC tissues. The overexpression of CAV1 abrogated the promotion of miR-96-5p on the OC cells proliferation and migration. Finally, we found that AKT signaling pathway was involved in this process. MiR-96-5p inhibited the phosphorylation of AKT and expression of down-stream proteins Cyclin D1 and P70 by targeting CAV1.ConclusionsThe above findings suggested that targeting miR-96-5p may be a promising strategy for OC treatment.
Highlights
Ovarian cancer (OC) is the second most common gynaecological malignancy
MiR-96-5p was up-regulated in OC tissues and cells First of all, we collected a panel OC patients (n = 23) and used Quantitative real-time PCR (qRT-PCR) assays to confirm the expression level of miR-96-5p between OC tissues and adjacent normal ovarian tissues
MiR-96-5p level was significantly higher in the serum samples of OC patients Secondly, we evaluated the expression level of miR-965p in serum samples from OC patients or health participants
Summary
Ovarian cancer (OC) is the second most common gynaecological malignancy. Ovarian cancer (OC) is the second most common gynaecological malignancy, accounting for approximately 4% of all females cancers in worldwide [1]. OC patients are usually diagnosed at an advanced stage due to its insidious onset. In this case, the initial treatment may cause a complete response, but these cancers often relapse. To date, there is no effective screening tool for early OC [1]. This is a growing interest in the potential utility of microRNAs (miRNAs) in the treatment of OC
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
